| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9023391 | DEXCEL PHARMA | Stable benzimidazole formulation |
Aug, 2025
(1 year, 10 months from now) | |
| US10076494 | DEXCEL PHARMA | Stable orally disintegrating pharmaceutical compositions |
Dec, 2036
(13 years from now) | |
| US10835488 | DEXCEL PHARMA | Stable orally disintegrating pharmaceutical compositions |
Dec, 2036
(13 years from now) | |
Omeprazole is owned by Dexcel Pharma.
Omeprazole contains Omeprazole.
Omeprazole has a total of 3 drug patents out of which 0 drug patents have expired.
Omeprazole was authorised for market use on 04 December, 2007.
Omeprazole is available in tablet, delayed release;oral dosage forms.
The generics of Omeprazole are possible to be released after 08 December, 2036.
Drugs and Companies using OMEPRAZOLE ingredient
Market Authorisation Date: 04 December, 2007
Treatment: NA
Dosage: TABLET, DELAYED RELEASE;ORAL
More Information on Dosage
OMEPRAZOLE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic